Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
Abstract Number: 1677 • ACR Convergence 2023
Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
Abhishek Abhishek¹, Nicholas Peckham², Corinna Pade³, Joseph Gibbons³, Lucy Cureton², Anne Francis², Vicki Barber², Jennifer Williams², duncan Appelbe², lucy Eldridge², patrick Julier², daniel Altmann⁴, James Bluett⁵, Tim Brooks⁶, Laura Coates², ines Rombach⁷, Amanda Semper⁶, Ashley Otter⁶, Ana Valdes¹, Jonathan Nguyen-Van-Tam¹, Hywel Williams¹, Aine McKnight³, Rosemary Boyton⁴ and jonathan Cook², ¹University of Nottingham, Nottingham, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴Imperial College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶UK Health Security Agency, Porton Down, United Kingdom, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Immunosuppressive treatments inhibit vaccine-induced immunity. We evaluated if a two-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein…
Abstract Number: 1732 • ACR Convergence 2023
Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA)
Huiyi Wang¹, Kangkang Luo¹, Shuxin Xu¹, Jiayin Zhou¹, Santi Chen², Jun wang², Wenzhao Li², Jing Zhao¹ and Cunxiang Ju¹, ¹GemPharmatech CO., Ltd., Nanjing, China, ²GemPharmatech LLC, La Jolla, CA
Background/Purpose: The differences between human and mouse immune systems make it challenging to accurately reflect the immunopathogenesis of autoimmune diseases in patients. Therefore, translational research…
Abstract Number: 1748 • ACR Convergence 2023
Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies
S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Breanna Butler¹, Jill Poole¹, Michael Duryee¹, Nozima Aripova¹, Carlos Hunter¹, Bridget Kramer¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…
Abstract Number: 1912 • ACR Convergence 2023
Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System
Khashayar Ahmadmehrabi¹, Navin Ravishankar², Diana Mekhiel³ and Zineb Aouhab³, ¹Loyola University Medical Center, Oak Park, IL, ²Indiana University Health, Indianapolis, IN, ³Loyola University Medical Center, Maywood, IL
Background/Purpose: Given the progressive joint damage and physical disability associated with uncontrolled Rheumatoid arthritis (RA), a treat-to target-strategy through the early utilization of disease-modifying antirheumatic…
Abstract Number: 2101 • ACR Convergence 2023
Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
Yusuke Miwa¹, Yuko Miwa-mitamura², Hiroi Tomioka³ and Michio Hosaka⁴, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Tokyo, Japan, ³Department of Psychiatry, School of Medicine, Showa University, Yokohama, Japan, ⁴Department of psychosomatic medicine, Katsuyama Clinic, Fujikawaguchiko, Japan
Background/Purpose: It has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods.…
Abstract Number: 2118 • ACR Convergence 2023
New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry
Robert Spandorfer¹, Kevin Kane², George Reed², Dimitrios Pappas², Joel Kremer², Jeffrey Curtis³ and Iris Navarro-Millán⁴, ¹Hospital for Special Surgery, Brooklyn, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
Abstract Number: 2135 • ACR Convergence 2023
Synovial Fluid High-density Lipoprotein (HDL)-miR-1246 Is Enriched in Patients with Inflammatory Arthritis Compared to Osteoarthritis and Increases Synovial Fibroblast IL-6 Expression
Olivia Posey¹, Qiong Wu¹, Anastasiia Phothisane¹, Christine Pham², Deborah Parks², Antonina Akk³, Danielle Michell¹, Kasey Vickers¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Washington University, St. Louis, MO, ³Washington University in St. Louis, St. Louis, MO
Background/Purpose: High-density lipoprotein (HDL), known for its anti-atherogenic reverse cholesterol transport function, also transports miRNAs between cells, altering cellular function. We found that compared to…
Abstract Number: 2151 • ACR Convergence 2023
Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial
Sara Tommasi¹, Richard Woodman¹, Michael Wiese², Michael Shanahan¹ and Arduino Mangoni¹, ¹Flinders University, Adelaide, Australia, ²University of South Australia, Adelaide, Australia
Background/Purpose: Treatment with methotrexate (MTX) has been shown to be associated with lower cardiovascular risk and lower blood pressure (BP) compared with other disease modifying…
Abstract Number: 2168 • ACR Convergence 2023
The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis
Gilad Halpert¹, Ori Moskovitch¹, Adi Anaki², Tal Caller¹, Omer Gendelman¹, Abdulla watad¹, Ruty Mehrian-Shai¹, Rachella Popovtzer², Boris Guilbord¹, Ori Segal¹ and Howard AMITAL¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Bar Ilan University, Ramat Gan, Israel
Background/Purpose: The use of biological treatment in patients with rheumatoid arthritis (RA) can induce non-specific immune suppression, which might result in higher rates of infections.…
Abstract Number: 2436 • ACR Convergence 2023
Characterizing Spatial Organization of Immune Infiltrates in Rheumatoid Arthritis Synovia Using Spatial Transcriptomic Analysis
Roopa Madhu¹, Kartik Bhamidipati¹, Anna Helena Jonsson¹, Fan Zhang², Lucy MacDonald³, Youngmi Kim⁴, Yi Cui⁴, STARS BWH¹, Accelerating Medicines Partnership Program RA SLE Network⁵, Mariola Kurowska-Stolarska³, Stefano Alvernini⁶, Ellen Gravallese⁷, Michael Brenner⁷, Soumya Raychaudhuri¹, Kevin Wei⁷ and ilya Korsunsky¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Aurora, CO, ³Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, United Kingdom, ⁴Nanostring, Seattle, WA, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by immune infiltration of the synovial tissue lining joints. RA is clinically heterogenous, with patients having…
Abstract Number: 2533 • ACR Convergence 2023
Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka², Eisuke Inoue³, Mai Abe¹, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai⁴, Rei Yamaguchi¹, Katsunori Ikari⁵, Ayako Nakajima⁶, Hisashi Yamanaka⁷ and Masayoshi Harigai⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjunku-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine,, Shinjunku-ku, Japan, ⁵Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁷Sanno Medical Center, Tokyo, Japan, ⁸Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…
Abstract Number: PP08 • ACR Convergence 2023
Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist
Yaideliz Acevedo, Global Healthy Living Foundation, Newark, NJ
Background/Purpose: I recall sitting in the doctor's office with my one-month-old baby in his stroller, hearing the words "You have rheumatoid arthritis." At 21, I…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].